Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO.1 TO FORM S-1 - Evoke Pharma Inc | d523612ds1a.htm |
| EX-5.1 - EX-5.1 - Evoke Pharma Inc | d523612dex51.htm |
| EX-10.3 - EX-10.3 - Evoke Pharma Inc | d523612dex103.htm |
| EX-24.2 - EX-24.2 - Evoke Pharma Inc | d523612dex242.htm |
| EX-10.5 - EX 10.5 - Evoke Pharma Inc | d523612dex105.htm |
| EX-10.7 - EX-10.7 - Evoke Pharma Inc | d523612dex107.htm |
| EX-10.6 - EX 10.6 - Evoke Pharma Inc | d523612dex106.htm |
| EX-10.9 - EX 10.9 - Evoke Pharma Inc | d523612dex109.htm |
| EX-10.2 - EX-10.2 - Evoke Pharma Inc | d523612dex102.htm |
| EX-10.8 - EX-10.8 - Evoke Pharma Inc | d523612dex108.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 19, 2013 (except for the last paragraph of Note 8, as to which the date is June [XX], 2013) in Amendment No. 1 to the Registration Statement (Form S-1) and related Prospectus of Evoke Pharma, Inc. for the registration of shares of its common stock.
Ernst & Young LLP
San Diego, California
The foregoing consent is in the form that will be signed upon the effectiveness of the reverse stock split as described in the last paragraph of Note 8 to the financial statements.
/s/ Ernst & Young LLP
San Diego, California
June 14, 2013